SEK115 -1.0 -0.9%
Last Trade - 12:45pm
| Market Cap | £495.2m |
| Enterprise Value | £414.0m |
| Revenue | £74.7k |
| Position in Universe | 483rd / 1829 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 184.8 | 0.87 | 28.9 | 454.7 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | June 29, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | 23 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 49,941,584 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Kungsbron 1, STOCKHOLM, 111 22, Sweden |
| Web | https://www.calliditas.se/ |
| Phone | +46 8 4113005 |
| Contact | () |
| Auditors | Ernst & Young AB |
As of 12:45pm, shares in Calliditas Therapeutics AB are trading at SEK115, giving the company a market capitalisation of £495.2m. This share price information is delayed by 15 minutes.
Shares in Calliditas Therapeutics AB are currently trading at SEK115 and the price has moved by 33.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Calliditas Therapeutics AB price has moved by 4.19% over the past year.
Of the analysts with advisory recommendations for Calliditas Therapeutics AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Calliditas Therapeutics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Calliditas Therapeutics AB is scheduled to issue upcoming financial results on the following dates:
Calliditas Therapeutics AB does not currently pay a dividend.
Calliditas Therapeutics AB does not currently pay a dividend.
Calliditas Therapeutics AB does not currently pay a dividend.
To buy shares in Calliditas Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Calliditas Therapeutics AB are currently trading at SEK115, giving the company a market capitalisation of £495.2m.
Here are the trading details for Calliditas Therapeutics AB:
Based on an overall assessment of its quality, value and momentum, Calliditas Therapeutics AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Calliditas Therapeutics AB are currently priced at SEK115. At that level they are trading at 89.66% discount to the analyst consensus target price of 0.00.
Analysts covering Calliditas Therapeutics AB currently have a consensus Earnings Per Share (EPS) forecast of -11.72 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calliditas Therapeutics AB. Over the past six months, the relative strength of its shares against the market has been -19.05%. At the current price of SEK115, shares in Calliditas Therapeutics AB are trading at -3.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Calliditas Therapeutics AB.
Calliditas Therapeutics AB's management team is headed by:
Here are the top five shareholders of Calliditas Therapeutics AB based on the size of their shareholding:
